Pulmonary vasodilator therapy in COPD-associated pulmonary hypertension: A real-world case series of 14 patients confirmed by right heart catheterization
Abstract
Rationale: Pulmonary vasodilator therapy in chronic obstructive pulmonary disease-associated pulmonary hypertension (COPD-PH) remains controversial, and real-world data describing which patients are selected for treatment after invasive hemodynamic confirmation are limited. We present a single-center case series of patients with RHC-confirmed COPD-PH treated with pulmonary vasodilators, focusing on clinical phenotype, hemodynamic profile, treatment patterns, and short-term outcomes.
Methods: We conducted a retrospective case series of adults with COPD-associated PH identified by right heart catheterization (RHC) between 2018 and 2023. Patients with isolated precapillary PH or combined pre- and postcapillary PH treated with pulmonary vasodilators within 1 month of RHC were included. Outcomes included major adverse cardiovascular events (MACE), all-cause mortality, and pulmonary complications.
Results: Among 200 patients with COPD-PH and a precapillary component, 14 patients (7%) received pulmonary vasodilator therapy after RHC and comprised the case series. Most had isolated precapillary PH (71%), severe PH by prior criteria (71%), and frequent cardiopulmonary comorbidities. Sildenafil monotherapy was used in 13/14 patients, while one received sildenafil plus macitentan. At 1-year follow-up, 5/13 patients with available data developed MACE, including 3 heart failure hospitalizations and 2 cardiovascular deaths. Among 4 patients with repeat RHC, 3 had higher PVR on follow-up…
How strong is the evidence?
Evidence Hub reads this as a case series, done in people. Its evidence level is 5 of 5 (Very low · case / narrative / animal / in vitro / in silico). Case reports, narrative reviews, and animal, cell or computer-model studies give the weakest evidence for human health. Reported size: 200 participants or records.
Read the paper
Related studies
- Drug repositioning: a brief overview
- Cyclic nucleotide phosphodiesterases in Drosophila melanogaster
- Time-resolved in silico modeling of fine-tuned cAMP signaling in platelets: feedback loops, titrated phosphorylations and pharmacological modulation
- Current View on Green Tea Catechins Formulations, Their Interactions with Selected Drugs, and Prospective Applications for Various Health Conditions
- In silico Structure-based Identification of Novel Acetylcholinesterase Inhibitors Against Alzheimer’s Disease
- Development and In Vitro Evaluation of Controlled Release Viagra® Containing Poloxamer-188 Using Gastroplus™ PBPK Modeling Software for In Vivo Predictions and Pharmacokinetic Assessments
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.